Natera, Inc. (NTRA) Earnings Call Transcripts

Natera, Inc.'s Latest Earnings Call - Q1 FY2026

In the first quarter of 2026, Natera, Inc. (NTRA) reported revenues of $697 million, reflecting a robust 39% year-over-year growth. The company achieved a significant milestone by delivering over 1 million units in a single quarter, driven by strong performance in women's health and oncology. Management raised their revenue guidance by over $120 million and increased gross margin expectations to 65% at the midpoint, indicating confidence in continued growth and operational efficiency.

Reported metrics

Guidance from management

Management raised full-year revenue guidance by over $120 million and increased gross margin expectations to 65% at the midpoint, reflecting confidence in continued growth.

What management said

Yes, that's a good question. We did, and I don't think we called that out in prepared remarks. But certainly, I think those storms that kind of hit maybe the end of January or somewhere in that time frame. We saw that there was just a step down in units, and we tried hard to recover a lot of those, but we definitely were not able to get the full recovery there. So I mean, despite having a record quarter really across...

Let me comment on that and then maybe Solomon, and Mike, if you want to comment, so first on -- prior of, I would say that's definitely been a tool that payers have used to not pay even for covered services. And any action that limits prior off for covered services is going to help our ASPs. So we commend the kind of strategies around that to make access to care easier for covered services. We do think that, that's a...

What analysts pressed on

Analysts expressed concerns regarding gross margin sustainability given the impact of increased volume on margins. There were also questions about the ramp-up of new sales representatives and their contribution to future growth.

Main topics on the call

• Record Unit Deliveries — Natera achieved a milestone of delivering over 1 million units in Q1, marking a 39% growth year-over-year. CEO Steve Chapman noted, "Q1 shows we are still in rapid growth mode," highlighting strong demand in women's heal...
• Fetal Focus Product Launch — The launch of the Fetal Focus product exceeded expectations, with nearly 200,000 focus orders anticipated. Management emphasized strong clinician interest, stating, "We are winning new customers and experiencing high cli...
• Increased Guidance — Management raised the revenue guidance by over $120 million and increased gross margin expectations to 65% at the midpoint. CFO Mike Brophy stated, "Given the fantastic start to the year, we are pleased to fully reset th...
• Oncology Growth — Oncology unit deliveries reached 249,000, a 55% increase year-over-year, with a notable increase of 24,000 units from Q4. This growth was attributed to strong clinical trial enrollments and successful data presentations,...

Read the full Natera, Inc. transcript (Q1 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 84 Natera, Inc. earnings call transcripts on record, spanning January 15, 2020 to August 6, 2026. Based on this history, Natera, Inc. reports quarterly. The most recent call on file is dated August 6, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

NTRA

Exchange

NasdaqGS

Country

US

Sector

Health Care

Industry

Biotechnology

Calls on record

84

First call

January 15, 2020

Most recent

August 6, 2026

Reporting cadence

quarterly